Re'equil

At nineteen, Vipul Gupta started going bald. What began as a private worry during college turned into an expensive, demoralizing tour of the personal-care aisle — every over-the-counter promise and prescription claim he could find, none of which held up — and ended, eventually, in a hair transplant, a surgical fix for a problem he'd been told a bottle could solve. The thing that lingered wasn't the hair loss itself but the sense of having been quietly oversold by an entire category. That grievance became a business plan. Gupta bootstrapped his venture rather than chasing early outside money, and built it around a deliberately unfashionable bet: not another fear-based 'natural' line trading on what it leaves out, but an efficacy-first cosmeceutical that names its actives and their concentrations on the label and stays fragrance-free and non-comedogenic. The name itself is the argument compressed into a word — restoring balance to skin and hair, and, just as pointedly, to the distance between what a product promises and what it actually delivers. The strategic insight that separated it from the pack was geographic: formulas were tuned for Indian skin tones and the country's heat and humidity, conditions most imported lines ignored. The proof of concept arrived in sun care, where lightweight, no-white-cast SPF formulations solved the specific complaint — heavy, chalky, greasy sunscreen — that had kept many Indian consumers from wearing any at all, and pulled the customer base past the million mark. Operating online-first and direct-to-consumer, the brand grew by explaining itself plainly to shoppers, so the transparency that motivated its founding doubled as its marketing engine. The honest caveat is scale of proof: its testing leans more on in-house and supplier work than a thick file of independent published trials. But as efficacy-first names go, it under-promises by design.

Sources:[1][2][3][4]